Variations in the reporting of
potentially confounding variables in studies investigating systemic treatments
for unresectable pancreatic cancer poses
challenges in drawing accurate comparisons between findings.
Pancreatic ductal adenocarcinoma (PDA) is a human
cancer with a poor prognosis. Gemcitabine, a key therapeutic agent for
metastatic PDA, and combination treatments have had only a modest impact on
extending survival.
PDA has a dismal prognosis and is often discovered at
an advanced stage with few therapeutic options. Present conventional regimens
for PDA are related with significant morbidity, decreased quality of life, and
a considerable financial burden. As a result, few patients turn to integrative
medicine therapies as sequential option after a treatment of PDA. Intravenous
pharmacologic ascorbic acid (PAA) is one such treatment. The use of PAA has
been Issues for many years, but more recent rigorous scientific research has
shown that there are significant blood concentration differences when ascorbic
acid is given parenterally when compared to oral dosing.
PDA accounts for most of advanced pancreatic cancer
cases and carries an expected 5-year survival rate of less than 6%.
Standard therapies for unresectable or metastatic
pancreatic cancer currently consist of gemcitabine-based regimens, combination
therapies such as folfirinox with or without radiation, and newer agents such
as nanoparticle-albumin-bound (nab)-paclitaxel and erlotinib, all of which
provide minimal response and a survival advantage measured in a few months.
The use of intravenous ascorbic acid (AA) in oncology
has a controversial history and has long been passionately debated.
Psychiatric symptoms may provide an earlier clue to
the presence of a growing pancreatic tumour. Yet, depression and anxiety are
very general symptoms and not something that can drive testing for pancreatic
cancer by itself.
Risk factors:
Age
The risk of developing pancreatic cancer increases
with age. Almost all patients are older than 45 years. Nearly 90% are older
than 55 years and more than 70% are older than 65.
Diabetes
Exocrine pancreatic cancer is more common in people
with this disease. The reason for this link is not known. Most of the risk is
found in people with type 2 diabetes. This type of diabetes most often starts
in adulthood. It is often related to being overweight or obese.
Pancreatic cancer seems to run in some families. In
some of these families, the high risk is due to an inherited syndrome. In other
families, the gene causing the increased risk of pancreatic cancer is not
known.
No comments:
Post a Comment